Yan-yan B. Liu

27 Dongming Road
Zhengzhou, 450008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma

Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma

Journal: Zhonghua yi xue za zhi

Published: May 07, 2026

Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogramming.

Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogramming.

Journal: Cancer letters

Published: October 23, 2025

Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogramming.

Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogramming.

Journal: Cancer letters

Published: October 23, 2025

Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma.

Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma.

Journal: Current treatment options in oncology

Published: February 02, 2025

Lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 86 patients.

Lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 86 patients.

Journal: Annals of hematology

Published: February 04, 2024

Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review.

Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review.

Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi

Published: November 25, 2022

Plasma EBV-DNA and peripheral blood mononuclear cell EBV-DNA have disparate clinical relevance in patients with extranodal NK/T-cell lymphoma.

Plasma EBV-DNA and peripheral blood mononuclear cell EBV-DNA have disparate clinical relevance in patients with extranodal NK/T-cell lymphoma.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: August 16, 2022

Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma.

Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma.

Journal: Cell reports. Medicine

Published: April 07, 2022

Natural killer cells: a promising immunotherapy for cancer.

Natural killer cells: a promising immunotherapy for cancer.

Journal: Journal of translational medicine

Published: February 21, 2022

MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.

MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.

Journal: Leukemia

Published: October 04, 2021

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 03, 2020

Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.

Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.

Journal: Immunotherapy

Published: August 21, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026